Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
100 shown of 2,511 total abstracts
  1. Abstract 95452026-09-03 · 14:00 CT · S100A
    CheckMate-559: Opdivo (nivolumab) 1L in metastatic melanoma
    L. Paz-Ares, C. Robert, R. Herbst, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  2. Abstract 104842026-09-02 · 18:15 CT · E450
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-185
    A. Spira, J. Cortes, P. Schmid, et al. · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  3. Abstract LBA4002LBA2026-09-03 · 15:45 CT · S100A
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-972
    H. Rugo, P. Schmid, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Plenary SessionMelanoma📄🖼️
  4. Abstract 97582026-09-03 · 20:15 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    G. Curigliano, M.C. Garassino, E. Winer · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  5. Abstract 104572026-09-01 · 18:15 CT · S100A
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    S. Peters, P. Schmid, H. Borghaei, et al. · Stanford Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  6. Abstract 101132026-09-02 · 21:00 CT · S100A
    CheckMate-731: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    S. Modi, C. Saura, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  7. Abstract LBA4006LBA2026-09-01 · 19:30 CT · S100A
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    J. Cortes, S. Tolaney · MD Anderson Cancer Center
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  8. Abstract 102202026-09-01 · 15:45 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    H. Borghaei, F. Andre, C. Saura, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  9. Abstract 98852026-09-02 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-789
    H. Borghaei, G. Curigliano, T. Mok, et al. · Massachusetts General Hospital
    Education SessionMelanoma📄🖼️
  10. Abstract 101532026-09-01 · 20:30 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-198
    F. Andre, A. Spira, M. Krop, et al. · Royal Marsden Hospital
    Poster Discussion SessionMelanoma📄🖼️
  11. Abstract 96822026-09-04 · 15:45 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-961
    S. Modi, A. Spira, C. Robert · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  12. Abstract 101652026-09-05 · 18:00 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-484
    S. Modi, M. Reck, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  13. Abstract 103902026-09-03 · 16:45 CT · S100A
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-632
    A. Spira, L. Paz-Ares · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  14. Abstract 101452026-09-03 · 13:15 CT · S100A
    CheckMate-955: Opdivo (nivolumab) 2L in metastatic melanoma
    N. Rizvi, J. Brahmer, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  15. Abstract TPS80142026-09-05 · 19:00 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-540
    H. Rugo, S. Modi, E. Winer · Royal Marsden Hospital
    Trials in Progress Poster SessionMelanoma📄🖼️
  16. Abstract 100182026-09-02 · 13:30 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-782
    M.C. Garassino, S. Peters, H. Borghaei · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  17. Abstract 97522026-09-01 · 19:00 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-743 study)
    G. Curigliano, T. Mok, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  18. Abstract 102432026-09-04 · 13:30 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-439 study)
    M. Reck, C. Robert, M. Krop, et al. · Mayo Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  19. Abstract 100262026-09-01 · 20:45 CT · S100A
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-603
    L. Paz-Ares, S. Tolaney, H. Borghaei, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  20. Abstract 97112026-09-04 · 19:00 CT · S406
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-660
    J. Cortes, C. Saura, M.C. Garassino, et al. · Karolinska Institute
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  21. Abstract TPS80202026-09-02 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-15 study)
    M. Krop, R. Herbst, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Trials in Progress Poster SessionMelanoma📄🖼️
  22. Abstract 104582026-09-05 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-602 study)
    R. Herbst, E. Winer, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  23. Abstract 95182026-09-04 · 14:00 CT · E450
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-230
    S. Modi, E. Winer, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  24. Abstract 97562026-09-03 · 14:00 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-451
    M. Krop, L. Paz-Ares, C. Robert, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  25. Abstract 95452026-09-04 · 16:30 CT · S406
    CheckMate-543: Opdivo (nivolumab) 3L+ in metastatic melanoma
    S. Peters, C. Saura, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  26. Abstract 95412026-09-03 · 19:15 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-668
    P. Schmid, N. Rizvi · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  27. Abstract TPS80262026-09-04 · 20:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-401 study)
    A. Spira, J. Cortes, R. Herbst, et al. · Institut Gustave Roussy
    Trials in Progress Poster SessionMelanoma📄🖼️
  28. Abstract 96882026-09-03 · 18:00 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-386 study)
    H. Borghaei, N. Rizvi · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  29. Abstract 99942026-09-01 · 16:45 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-913 study)
    J. Brahmer, C. Saura · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  30. Abstract 104462026-09-03 · 21:30 CT · S100A
    CheckMate-290: Opdivo (nivolumab) 2L in metastatic melanoma
    S. Tolaney, S. Modi, C. Robert, et al. · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  31. Abstract 96272026-09-03 · 13:30 CT · S406
    CheckMate-534: Opdivo (nivolumab) 3L+ in metastatic melanoma
    M.C. Garassino, J. Cortes, M. Krop, et al. · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  32. Abstract 98922026-09-03 · 18:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-72
    S. Peters, C. Robert, C. Saura · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  33. Abstract 102442026-09-04 · 18:00 CT · Arie Crown Theater
    CheckMate-894: Opdivo (nivolumab) adjuvant in metastatic melanoma
    C. Robert, S. Antonia, E. Winer, et al. · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  34. Abstract 101992026-09-02 · 15:15 CT · S406
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-664
    R. Herbst, J. Brahmer, J. Cortes · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  35. Abstract 95732026-09-02 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-281 study)
    E. Winer, H. Borghaei, S. Peters · Mayo Clinic
    Poster Discussion SessionMelanoma📄🖼️
  36. Abstract e120352026-09-03 · 18:15 CT · S406
    CheckMate-30: Opdivo (nivolumab) adjuvant in metastatic melanoma
    J. Brahmer, S. Modi, E. Winer, et al. · University of Chicago
    Publication OnlyMelanoma📄🖼️
  37. Abstract 97622026-09-01 · 14:00 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-657
    E. Winer, M.C. Garassino, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  38. Abstract 99602026-09-02 · 15:15 CT · Hall B1
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-750
    H. Borghaei, J. Cortes, C. Saura, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  39. Abstract 98932026-09-03 · 15:30 CT · Hall B1
    KEYNOTE-818: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    N. Rizvi, H. Borghaei, J. Cortes, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  40. Abstract 98392026-09-01 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-375
    E. Winer, H. Borghaei, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  41. Abstract 103232026-09-01 · 14:15 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-443
    H. Borghaei, F. Andre, T. Mok, et al. · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  42. Abstract 97022026-09-02 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-201 study)
    H. Borghaei, P. Schmid · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  43. Abstract 100912026-09-04 · 20:00 CT · Arie Crown Theater
    CheckMate-634: Opdivo (nivolumab) 3L+ in metastatic melanoma
    H. Borghaei, H. Rugo, J. Cortes, et al. · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  44. Abstract 95212026-09-04 · 21:15 CT · S406
    CheckMate-912: Opdivo (nivolumab) 3L+ in metastatic melanoma
    M.C. Garassino, R. Herbst, L. Paz-Ares, et al. · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  45. Abstract 97952026-09-01 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-353 study)
    T. Mok, P. Schmid, S. Antonia · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  46. Abstract 97302026-09-03 · 13:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-9
    H. Borghaei, A. Spira · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  47. Abstract 97222026-09-05 · 14:00 CT · S100A
    KEYNOTE-435: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    M.C. Garassino, T. Mok, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  48. Abstract 95862026-09-04 · 21:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-599 study)
    M. Krop, C. Saura, P. Schmid, et al. · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  49. Abstract 97922026-09-05 · 15:00 CT · S100A
    CheckMate-231: Opdivo (nivolumab) 1L in metastatic melanoma
    C. Robert, S. Peters, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  50. Abstract 96352026-09-02 · 13:30 CT · S406
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-551
    T. Mok, S. Tolaney, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  51. Abstract 96472026-09-05 · 15:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-342
    C. Robert, S. Tolaney, H. Rugo, et al. · Stanford Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  52. Abstract 100292026-09-03 · 20:00 CT · S406
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-879
    S. Modi, S. Tolaney, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  53. Abstract 97402026-09-04 · 18:45 CT · S100A
    CheckMate-279: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    C. Robert, C. Saura, A. Spira · Institut Gustave Roussy
    Education SessionMelanoma📄🖼️
  54. Abstract LBA4053LBA2026-09-03 · 13:30 CT · Hall B1
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-479
    M. Krop, S. Antonia, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionMelanoma📄🖼️
  55. Abstract 101242026-09-02 · 19:45 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-100 study)
    S. Tolaney, M. Reck, R. Herbst · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  56. Abstract 95522026-09-05 · 14:00 CT · S100A
    CheckMate-655: Opdivo (nivolumab) 3L+ in metastatic melanoma
    G. Curigliano, L. Paz-Ares, F. Andre, et al. · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  57. Abstract 96102026-09-05 · 16:15 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-84 study)
    A. Spira, P. Schmid, H. Borghaei · University of Chicago
    Poster Discussion SessionMelanoma📄🖼️
  58. Abstract 101722026-09-01 · 16:00 CT · Hall B1
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-825
    H. Borghaei, M.C. Garassino, J. Brahmer, et al. · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  59. Abstract 97382026-09-02 · 19:15 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-814
    S. Modi, J. Cortes, M. Krop, et al. · Cleveland Clinic
    Education SessionMelanoma📄🖼️
  60. Abstract 102762026-09-03 · 16:00 CT · Hall B1
    KEYNOTE-96: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    J. Cortes, A. Spira, R. Herbst, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  61. Abstract 97452026-09-05 · 21:30 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-560
    S. Peters, H. Borghaei · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  62. Abstract 96902026-09-02 · 15:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-306
    J. Cortes, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  63. Abstract 101222026-09-03 · 16:00 CT · Hall B1
    KEYNOTE-307: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    R. Herbst, C. Saura, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  64. Abstract e120632026-09-02 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-124 study)
    J. Cortes, E. Winer, C. Saura · Vall d'Hebron Institute of Oncology
    Publication OnlyMelanoma📄🖼️
  65. Abstract TPS80642026-09-01 · 13:45 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-215
    J. Brahmer, N. Rizvi, H. Rugo, et al. · MD Anderson Cancer Center
    Trials in Progress Poster SessionMelanoma📄🖼️
  66. Abstract 100932026-09-03 · 19:00 CT · S100A
    KEYNOTE-278: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    R. Herbst, E. Winer · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  67. Abstract 96622026-09-05 · 19:15 CT · Arie Crown Theater
    CheckMate-21: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    E. Winer, S. Peters · Royal Marsden Hospital
    Poster Discussion SessionMelanoma📄🖼️
  68. Abstract 102232026-09-04 · 16:15 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-522 study)
    T. Mok, E. Winer, M. Reck, et al. · National Cancer Center Japan
    Clinical Science SymposiumMelanoma📄🖼️
  69. Abstract LBA4068LBA2026-09-05 · 18:30 CT · S100A
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-112
    H. Borghaei, G. Curigliano, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Plenary SessionMelanoma📄🖼️
  70. Abstract 96202026-09-01 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-320 study)
    T. Mok, C. Saura · University of Chicago
    Poster SessionMelanoma📄🖼️
  71. Abstract 102872026-09-01 · 18:45 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-106 study)
    L. Paz-Ares, P. Schmid, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  72. Abstract 103612026-09-02 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-494 study)
    H. Rugo, H. Borghaei · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  73. Abstract 99132026-09-03 · 14:00 CT · E450
    CheckMate-617: Opdivo (nivolumab) 3L+ in metastatic melanoma
    R. Herbst, C. Saura, J. Cortes, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  74. Abstract 95072026-09-02 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-809
    G. Curigliano, M. Reck · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  75. Abstract TPS80742026-09-05 · 21:30 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-348
    N. Rizvi, R. Herbst, S. Tolaney, et al. · National Cancer Center Japan
    Trials in Progress Poster SessionMelanoma📄🖼️
  76. Abstract 97482026-09-01 · 13:30 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-32
    E. Winer, P. Schmid, M. Krop, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  77. Abstract 96612026-09-02 · 20:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-710
    C. Saura, S. Modi, J. Brahmer, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  78. Abstract 97902026-09-04 · 19:30 CT · S100A
    KEYNOTE-778: Keytruda (pembrolizumab) 3L+ in metastatic melanoma
    G. Curigliano, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  79. Abstract 101692026-09-03 · 21:15 CT · S100A
    KEYNOTE-213: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    C. Robert, P. Schmid, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  80. Abstract 100112026-09-01 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-625 study)
    S. Modi, S. Antonia · University of Chicago
    Clinical Science SymposiumMelanoma📄🖼️
  81. Abstract 102622026-09-01 · 20:15 CT · Arie Crown Theater
    CheckMate-320: Opdivo (nivolumab) maintenance in metastatic melanoma
    C. Robert, F. Andre, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  82. Abstract 97322026-09-02 · 19:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-555 study)
    P. Schmid, J. Cortes, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  83. Abstract 104852026-09-05 · 18:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-645
    M. Krop, S. Tolaney, H. Borghaei, et al. · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  84. Abstract 103022026-09-05 · 13:30 CT · Arie Crown Theater
    KEYNOTE-665: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    L. Paz-Ares, R. Herbst, G. Curigliano, et al. · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  85. Abstract LBA4084LBA2026-09-05 · 13:45 CT · S406
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-541
    S. Modi, A. Spira, S. Peters, et al. · Chinese University of Hong Kong
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  86. Abstract 99942026-09-05 · 18:30 CT · S100A
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-75
    R. Herbst, M.C. Garassino, C. Saura, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  87. Abstract 104262026-09-04 · 21:15 CT · S406
    KEYNOTE-820: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    L. Paz-Ares, S. Peters, E. Winer · Massachusetts General Hospital
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  88. Abstract 95952026-09-04 · 15:45 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-44 study)
    S. Peters, L. Paz-Ares, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  89. Abstract e120882026-09-04 · 15:30 CT · E450
    CheckMate-371: Opdivo (nivolumab) adjuvant in metastatic melanoma
    S. Tolaney, R. Herbst, M. Reck, et al. · Karolinska Institute
    Publication OnlyMelanoma📄🖼️
  90. Abstract 95042026-09-04 · 15:00 CT · S100A
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-974
    S. Peters, H. Rugo, F. Andre, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  91. Abstract 98242026-09-05 · 16:30 CT · S406
    KEYNOTE-284: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    E. Winer, G. Curigliano, S. Peters, et al. · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  92. Abstract 98032026-09-02 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-552 study)
    J. Brahmer, H. Rugo, J. Cortes, et al. · Royal Marsden Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  93. Abstract 97092026-09-05 · 19:30 CT · S406
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-496
    S. Tolaney, J. Cortes, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  94. Abstract 104192026-09-01 · 15:45 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-313 study)
    A. Spira, S. Tolaney, T. Mok, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  95. Abstract 98712026-09-02 · 14:45 CT · Hall B1
    KEYNOTE-457: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    P. Schmid, G. Curigliano, M. Reck · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  96. Abstract 104532026-09-01 · 19:00 CT · S100A
    Long-term follow-up of Keytruda adjuvant for metastatic melanoma: KEYNOTE-486
    L. Paz-Ares, T. Mok, J. Brahmer · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  97. Abstract 104422026-09-04 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-321 study)
    E. Winer, M. Reck, G. Curigliano · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  98. Abstract 101132026-09-04 · 16:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-369
    J. Brahmer, A. Spira, S. Antonia · Chinese University of Hong Kong
    Education SessionMelanoma📄🖼️
  99. Abstract 98462026-09-01 · 19:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-608 study)
    T. Mok, S. Tolaney · Chinese University of Hong Kong
    Poster Discussion SessionMelanoma📄🖼️
  100. Abstract 96162026-09-03 · 20:15 CT · Hall B1
    KEYNOTE-133: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    S. Tolaney, H. Rugo, A. Spira, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.